Brainstorm Cancer Therapeutics

Brainstorm Cancer Therapeutics is an oncology-focused biotechnology company dedicated to redefining drug delivery across the blood-brain barrier. Launched in May 2026 by the New Haven-based venture creation platform CapeHaven, the company is built on breakthrough research from Yale University. Brainstorm's proprietary platform utilizes sustained-release, tumor-adherent nanoparticles to deliver therapeutic payloads, such as PARP inhibitors, directly into the cerebrospinal fluid. This innovative approach is designed to treat difficult-to-reach brain cancers, including pediatric medulloblastoma, glioblastoma, and leptomeningeal metastases, while minimizing systemic toxicity.